rss
Thorax 65:173-177 doi:10.1136/thx.2009.113498
  • Interstitial lung disease

The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference

  1. Kevin K Brown1
  1. 1Interstitial Lung Disease Program and Autoimmune Lung Center, National Jewish Health, Denver, Colorado, USA
  2. 2Division of Psychosocial Medicine, National Jewish Health, Denver, Colorado, USA
  3. 3Department of Internal Medicine I, University of Munich, Germany
  4. 4Division of Pulmonary and Critical Care Medicine, University of California San Francisco, California, USA
  5. 5Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, Washington DC, USA
  1. Correspondence to Dr Kevin K Brown, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA; brownk{at}njc.org
  • Received 8 January 2009
  • Accepted 29 December 2009
  • Published Online First 8 December 2009

Abstract

Rationale The response characteristics of the 6 minute walk test (6MWT) in studies of idiopathic pulmonary fibrosis (IPF) are only poorly understood, and the change in walk distance that constitutes the minimum important difference (MID) over time is unknown.

Objectives To examine changes over time in distance walked (ie, 6MWD) during the 6MWT and to estimate the change in distance that constitutes the MID in patients with IPF.

Methods Data from a recently completed trial that included subjects with IPF who completed the 6MWT, Saint George's Respiratory Questionnaire (SGRQ) and forced vital capacity (FVC) at 6 and 12  months were used to examine longitudinal changes in 6MWD. Both anchor- and distribution-based approaches as well as linear regression analyses were used to determine the MID for 6MWD. The SGRQ Total score and FVC were used as clinical anchors.

Main results Among 123 subjects alive and able to complete the 6MWT at both follow-up time points, 6MWD did not change significantly over time (378.1 m at baseline vs 376.8 m at 6 months vs 361.3 m at 12 months, p=0.5). The point estimate for the 6MWD MID was 28 m with a range of 10.8–58.5 m.

Conclusion In a group of patients with IPF with moderate physiological impairment, for those alive and able to complete a 6MWT, 6MWD does not change over 12 months. At the population level, the MID for 6MWD appears to be ∼28 m. Further investigation using other anchors and derivation methods is required to refine estimates of the MID for 6MWD in this patient population.

Footnotes

  • Funding Actelion Pharmaceuticals funded the performance of the underlying BUILD-1 trial that investigated the efficacy of bosentan in the treatment of idiopathic pulmonary fibrosis. No additional external funding was obtained. All authors had full access to all the data in this study. The corresponding author had final responsibility for the decision to submit the paper for publication.

  • Competing interests JB, RMduB, TEK, GR and KKB served on the steering committee for the BUILD-1 trial, sponsored by Actelion Pharmaceuticals. JJS has served as a paid consultant to Actelion Pharmaceuticals. FSW has no competing interests to declare.

  • Ethics approval This study was approved by the appropriate independent ethics committees or institutional review boards.

  • Provenance and peer review Not commissioned; externally peer reviewed.